Loading stock data…
LQDA
$53.13+10.74 (+25.35%)
Market ClosedLast close May 11
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Liquidia Corporation in the Healthcare sector is trading at $53.13. The stock is currently near its 52-week high of $53.93, remaining 67.9% above its 200-day moving average. Technical signals show overbought RSI of 94 and bullish MACD crossover, explaining why LQDA maintains its current momentum and trend strength. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 94) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$53.13
Potential Upside
5%
Whystock Fair Value$55.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.46
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-102.90%
Volume
Today's trading volume
6.83M
Recent News
Liquidia Corporation Q1 2026 Earnings Call Summary
Moby summary of Liquidia Corporation's Q1 2026 earnings call
Why This Biotech Stock Just Broke Out To A Record High
Liquidia stock broke out to a record high Monday after the company smashed first-quarter sales expectations.
Liquidia (LQDA) Q1 2026 Earnings Transcript
The first is that in the third full quarter on the market, YUTREPIA is now leading the growth of the inhaled prostacyclin category. YUTREPIA is well on its way to becoming the anchored inhaled therapy for patients with PAH and PH-ILD. For example, just since the end of February, the number of physicians who have prescribed YUTREPIA to 5 or more patients has grown 25% to approximately 270 physicians.
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
Liquidia Q1 Earnings Call Highlights
Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. On the company’s earnings call, Chi